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METHODS: We examined the concentration of the pharmaceutical market by using 
the Herﬁndahl-Hirschmann Index. We calculated the index for 12 different medicine 
groups in 2002–2008. Ten of these groups were prescription medicines and two were     
self-care medicines. The index is calculated by summing up the squares of the market 
shares for all the ﬁrms operating in the medicine group. It is important that all medi-
cines in each group can be substituted to each other. The index value varies between 
1/n  1, n  ﬁrms. Greater value of the HHI indicates greater concentration. If HHI 
is below 0.18 there is no concentration at all. RESULTS: In 2002 the total HHI 
average for the 12 groups was 0.30 as in 2008 it was 0.22. In anti-dementia drugs    
the index dropped from 0.48 to 0.23. In triptans the index dropped from 0.40 to 0.17. 
The smallest index was seen in antiallergics. In 2002 the index in this group was 0.14 
and in 2008 it was 0.12. In 2008 the most concentrated group according to the index 
was the protone pump inhibitors. The index in this group was 0.38. CONCLUSIONS: 
From 2002 to 2008 the concentration in medicine groups has clearly diminished. The 
difference between these groups is partly due to patents. The two self-care medicine   
groups used in the study are clearly less concentrated than the prescription medicine 
groups. However, the average for all 12 groups is 0.22 and exceeds the index point 
of 0.18. This indicates that among the medicine groups used in calculations the market 
is still concentrated.
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OBJECTIVES: To examine if the introduction of a lump sum reimbursement system 
for pharmaceuticals in Belgian hospitals for hospitalized patients resulted in shifts 
in Health Insurance expenses (third party payer) for pharmaceuticals from an in-
patient setting (hospitalized patients) to an out-patient setting (day clinic, public 
pharmacies, . . .), based on an analysis of ﬁnancial data of NIHDI. METHODS: In july 
2006, a partial (approximately 75% of the expenses) lump sum reimbursement 
system was introduced for standard medication (excluding new expensive drugs, 
oncolytics, orphan drugs, . . .) ﬁxing budgets per hospital, per hospitalization, based 
on patient proﬁles (APRDRG, All patients Reﬁned Diagnosis Related Groups) and 
ﬁnancial data. Using registered ﬁnancial data from NIHDI the evolution of the Health 
Insurance expenses for pharmaceuticals in hospitals was examined. RESULTS: 
The yearly expenses for pharmaceuticals for hospitalized patients grew with 8.0%, 
0.2%, 2.0%, 0.1% and 1.6% in the period 2003–2008. For patients in day 
clinic the growth was respectively 23.7%, 11.7%, 5.8%, 19.3% and 17,9%. 
For patients in public pharmacies these ﬁgures were 8.2%, 1.2%, 2.3%, 6.2% 
and 12.2%. CONCLUSIONS: Evaluation of the data shows no changes in the trend 
in evolution of the expenses for any type of patients other than leveling of the growth 
in the period 2005–2006—similar to the evolution of expenses for pharmaceuticals 
in the other OECD countries—and a additional growth in expenses in public pharmacies 
(6,2%) due to the inclusion of self-employed persons in the general system for com-
pulsory health insurance in 2008. Analysis shows no shifts in expenses from one 
setting to another.
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OBJECTIVES: In view of the 6-fold increase in drug expenditure over the past decade 
in Ireland, we set out to identify primary areas of utilisation and expenditure under 
the Community Drugs Schemes and explore strategies for cost containment. 
METHODS: We examined the Statistical Analysis of Claims and Payments for 
2007/2008 from the Primary Care Reimbursement Service (PCRS). This is a deﬁnitive 
measure of general practitioner prescribing rates and enabled us to determine utiliza-
tion and expenditure. We applied the autoregressive integrated moving average 
(ARIMA) model to the national prescribing database to predict future expenditure on 
medicines. RESULTS: In 2008 expenditure under the Community Drugs Schemes was 
a2.289 billion with over 60.5 million prescription items. The ARIMA model predicts 
that expenditure will continue to rise reaching a2.3–a3 billion by 2012. The 60.5 
million prescription items are distributed as follows: General Medical Services Scheme 
(GMS) 73%, Long Term Illnesses Scheme 4% (both free to patients), Drug Payments 
Scheme 22%, High Technology Drugs and others account for the remaining 1%. The 
major therapeutic classiﬁcations by cost under the GMS are Cardiovascular System 
23.9%, Nervous System 20.5%, Alimentary Tract and Metabolism 15.4%. Cost 
containment measures could include: increasing generic drug utilisation rates from 
18.3% (2.4% unbranded, 15.9% branded; EU average ^50%); decreasing wholesale 
margin from 15%; changing current drug schemes by introducing disinvestment 
measures and patient co-payments; reducing the pharmacy 50% mark-up and intro-
ducing reference pricing whilst continuing to reward innovation. CONCLUSIONS: 
It is clear that the current trend of increasing drug expenditure will continue and 
the measures we have suggested above would be efﬁcient strategies for cost 
containment.
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OBJECTIVES: Global pharmaceutical companies often conduct coordinated, multi-
country studies to elicit information from payers and those who inﬂuence their deci-
sions. Such studies can inﬂuence global product value strategy and increase the 
likelihood of positive pricing and reimbursement (P&R) decisions. Differences in P&R 
systems across markets must be considered. The aim of this study was to compare 
payer roles in three pharmaceutical markets (UK, Spain, Canada), and to evaluate 
the usefulness of various qualitative research methods in eliciting information to 
inform a global product value strategy. METHODS: We conducted a review of pub-
licly available guidance and qualitative payer research to develop a framework for 
comparing optimal approaches to qualitative payer research. We compared the 
levels at which pricing, reimbursement, and market access decisions are made (e.g., 
national, regional, local, hospital), bodies inﬂuencing payer decisions (e.g., health 
technology assessment agencies), and the processes of engagement among physicians, 
patients, and payers. Implications of various qualitative and quantitative research 
techniques on a pharmaceutical company’s ability to devise an effective global strategy 
are discussed. RESULTS: Treatment location (outpatient drug, hospital only) and type 
of prescriber must be considered when determining the research strategy in Spain. 
In Canada, provincial drug plans make reimbursement decisions for outpatient 
drugs considering Common Drug Review recommendations. Hospital formulary com-
mittees assess drugs for hospital use. NICE, the Scottish Medicines Consortium and 
the All Wales Medicines Strategy Groups make decisions at the national level in the 
UK while Primary Care Trusts make funding decisions in the absence of NICE 
appraisal in England. CONCLUSIONS: For multi-country payer research to be useful 
for devising a global value strategy it is important to understand the pricing and 
reimbursement systems in different countries and to identify properly the key 
stakeholders.
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MIDDLE INCOME COUNTRIES—WHAT INFLULENCE DOES IT HAVE ON 
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HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES
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OBJECTIVES: Assessment of health technology (HTA), including pharmaceuticals, 
devices, procedures and organizational systems plays an increasingly important 
role in health care systems by providing structured, evidence-based input to policy-
making. HTA is ﬁrmly established in Europe, North America and Australasia, and is 
growing rapidly in Asia and Latin America. We investigated the organisation and 
inﬂuence of HTA in middle-income countries on real decision-making over pharam-
ceutical budgets. METHODS: We selected middle-income countries where HTA 
activities are establihsed to some extent: Argentina, Brazil, China, Colombia, Israel, 
Mexico, Philippines, Korea, Taiwan, Thailand, and Turkey. We collected and reviewed 
relevant information to describe the health care and reimbursement systems and how 
HTA relates to coverage decision making of pharmaceuticals using a common tem-
plate. The country proﬁles were supplemented by information from a structured 
web-survey among professionals working in public and private health insurance, 
industry, regulatory authorities, ministries of health, academic units or HTA agencies. 
RESULTS: The use and implementation of HTA recommendations in reimbursement 
decision-making is still in its early stages. We found that in South Korea, Taiwan, 
Brasil and Mexico HTA was more developed, with guidelines for manufacturers 
submissions, a link to the pricing of new treatments and some requirement for data 
to be adapted for local costs epidemiology. CONCLUSIONS: The study provides 
evidence of the development of HTA in coverage decision making in middle-income 
countries. Increased health care spending and the resulting access to modern technol-
ogy give a strong impetus to HTA. The assessment and regulation of pharmaceuticals 
are advanced in relation to other technologies. HTA is developing with uneven speed 
in middle-income countries; many countries are building on the organisational and 
methodological experience from established HTA agencies in Europe, Australia and 
Canada.
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OBJECTIVES: Elicit the individual willingness to pay (WTP) for a QALY. METHODS: 
Web-based contingent analysis included 1091 respondents, representative of the Dutch 
population. Individuals solved 5 scenarios with two health states each. They initially 
valued health states on VAS scale, then indicated which health state was worse and 
ﬁnally expressed their WTP for avoiding a given decline in health. WTP was elicited 
in an open-ended format and from a payment scale. Respondents had to indicate the 
degree of certainty in the answers provided. WTP/QALY was calculated one for every 
utility elicitation technique, WTP elicitation technique (payment scale and open-ended 
questions) and each scenario. The heterogeneity in WTP/QALY ratios was examined 
from the perspective of 1) household income, and 2) the level of certainty in WTP 
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answers. A clustered multivariate regression analysis explored theoretical validity of 
results. RESULTS: On average, respondents are willing to pay a12,920 (VAS scores) 
and a24,549 for a QALY (EuroQoL tariffs). Subgroup analysis showed great variation 
in WTP/QALY between income groups—from a5,000 in the lowest to a87,000 for a 
QALY in the highest group. Respondents that indicated a high level of certainty 
exhibited marginally higher WTP. Regression analyses showed a consistent relation-
ship between income, other demographics and WTP/QALY. CONCLUSIONS: Indi-
vidual WTP/QALY should be seen as a step to a sound empirical value of the social 
cost-effectiveness threshold in the Netherlands. Estimates elicited in this study are 
similar to those found in other empirical studies and are systematically lower than 
often cited thresholds, largely unsupported by empirical evidence (i.e. $50,000). 
However, there is a wide gap between the social and private value of a QALY. Future 
research should move towards estimating the social value of the cost-effectiveness 
threshold and align with the perspective of decision-makers thus creating a truly valu-
able decision-making tool.
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OBJECTIVES: Innovative point-of-care diagnostics are likely to be having a strong 
impact on health care. The aim of this study is to conduct an early assessment of            
point-of-care chips. These chips can detect many particles and, consequently, many 
product-market combinations can be developed. This study investigates the impact of 
potential point-of-care applications in health care and to quantify the impact in terms 
of their likely cost-effectiveness. METHODS: The Analytic Hierarchy Process (AHP); 
a technique for multi-criteria analysis, and Markov modeling were applied in this early 
assessment. The AHP was used to prioritize six potentially attractive product-market 
combinations (PCM’s). For estimating the future cost-effectiveness of the most attrac-
tive PMC’s, Markov health state transition models were developed. Two Markov 
models were constructed; models for a potassium chip for both stage 5 CKD patients 
as well as heart failure (HF) patients which suffer from edemas. RESULTS: AHP 
identiﬁed clinical gain as being the most important criterion to assess the attractiveness 
of a PMC, followed by market potential, attitude of professionals, R&D barriers and 
implementation barriers. Regarding these criteria, a potassium-chip for Chronic 
Kidney Disease (CKD) and Heart Failure (HF) patients was calculated to be the most 
attractive alternative. Markov model cohort simulation yielded incremental cost-effec-
tiveness ratios (ICERs). The point-of-care chip appeared not to be cost-effective for 
preventing hyperkalemia in stage 5 CKD patients. For HF patients suffering from 
edemas the chip was estimated to be cost-effective and could provide a valuable asset 
to current treatment. CONCLUSIONS: The AHP is valuable in supporting the iden-
tiﬁcation of potentially attractive product-market combinations. For the best combina-
tions, Markov modeling can subsequently provide a more in-depth analysis of the 
future cost-effectiveness.
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ECONOMIC EVALUATIONS
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OBJECTIVES: At present the costs and effects of providing informal care are often 
ignored in economic evaluations. This is problematic since considering informal      
care a ‘zero cost’ substitute for formal care may result in non-optimal decisions from      
a societal perspective, at the burden of carers. This study further investigates 
the validity of the CarerQol instrument, which values the full impact of informal 
care on caregivers. The CarerQoL consists of seven burden dimensions (CarerQol-7D)      
and a visual analogue scale measuring happiness (CarerQol-VAS). METHODS: 
A questionnaire was distributed by mail among a sample of caregivers (n  1100) 
via regional support centres for informal caregivers throughout the Netherlands. 
Construct validity (n  249) was tested with Spearman’s correlation coefﬁcients of        
the CarerQol-VAS and the CarerQol-7D and two measures of subjective burden 
and the utility of care giving. Clinical validity was evaluated by the multivariate cor-   
relation between the CarerQol-VAS and characteristics of the caregiver, care recipient 
and care situation. Differences in CarerQol-VAS scores among caregivers are explained 
with subgroup multiple linear regression analyses and principal component analyses. 
RESULTS: CarerQol-VAS scores were negatively associated with burden and posi-
tively with utility of caring. The seven dimensions of the CarerQol-7D were also 
associated with burden and utility of caring in the expected direction, for six dimen- 
sions the associations were statistically signiﬁcantly. Signiﬁcant associations with 
CarerQol-VAS scores were found for a range of characteristics, including duration 
and intensity of care, relationship between carer and patient, carer education level and 
patient age. CONCLUSIONS: Our results further support the construct and clinical 
validity of the CarerQol and thus underlines the relevance of this instrument 
for including informal care effects in economic evaluations. The next, necessary 
step in the development of the CarerQol concerns the establishment of tariffs for the             
caring situations deﬁned by the seven dimensions. This is the topic of coming           
research.
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OBJECTIVES: To assess the provision of health care and reimbursement in ambula-
tory palliative care in Germany. METHODS: A survey was conducted among 1000 
ofﬁce-based physicians in January 2009, covering e.g. the following topics: quantity 
of palliative care, its reimbursement and resource use due to side effects of opioid 
medication. RESULTS: A total of 314 physicians (30% response rate) were included 
in the statistical analysis. A total of 63.7% were general practitioners (GP), 36.3% 
specialists. A total of 67% of all physicians were additionally trained in palliative 
medicine. Fifty percent estimate efforts associated with palliative care to be at least 
1.5 times higher compared to patients with other serious conditions. On average GPs 
(specialists) visit palliative patients 5.9 (3.7) times per quarter at home (2.3 (1.2) visits 
for non-palliative though sick patients, p  0.01). Overall palliative patients also 
require more ofﬁce consultations compared to nonpalliative patients (4.6 vs. 3.5, GP 
4.7 vs. 3.5, specialist 4.5 vs. 3.4, all p  0.01) and need more time per visit (17.5 min 
versus 11.5 min) (p  0.01). Constipation is the most frequent side-effect in opioid 
medication and requires app. 20% more time and effort compared to no constipation. 
According to the German Remuneration Scheme (EBM) GPs (specialists) receive a 
lump-sum per quarter for ofﬁce consultations, irrespective of number or length of visit 
or palliative status, of app. a35 (31) and a mean of app. a7.50 (7) for a basic consulta-
tion. Hence, 95% (60%) of the participants trained in palliative care evaluate the 
reimbursement and health care structures in the German setting as insufﬁcient or very 
insufﬁcient. CONCLUSIONS: Compared to non-palliative there is a higher need for 
medical resources among palliative patients—a need that is currently not reﬂected in 
the remuneration system. Considering the demographic development and the resulting 
signiﬁcance of palliative care further research should focus on identifying room for 
improvement and corresponding strategies.
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OBJECTIVES: To assess the prescription drug knowledge and the impact of counsel-
ing on it in patients visiting a public teaching hospital. METHODS: A standardized 
questionnaire of prescription drug knowledge that embraces 8 questions e.g. drug 
name, indication, side effect, dose, frequency of dosing, dosage schedule, storage and 
missed dose action of prescription drugs was used. Education level was set as group-1 
illiterate patients, group-2 education up to secondary school and group-3 graduate 
patients. The patients were scored 1 for every correct answer, with a maximum of 8. 
The overall scores were then categorized as low (3), medium (3–6) and high (6). 
Patients were counseled by oral, written, oral-pictorial combine, written-pictorial 
combine and oral-written-pictorial combine for all the questions. Post counseling 
evaluation was performed to assess the impact of patient counseling. RESULTS: Total 
753 patients were assessed. Patient’s knowledge about prescription drug name, side 
effect, dose and missed dose action was poor. The prescription drug knowledge score 
was low (3) in group-1 and the patients of acute drug treatment. Whereas, medium 
(3–6) knowledge score was observed in group-2, group-3 and patients of chronic drug 
treatment. The overall score was improved from 3.43 o 1.47 to 6.20   o 1.26 after  
counseling in all enrolled patients. After counseling overall score was improved from 
2.88 o 1.40 to 6.01   o 1.16 and from 3.71    o 1.43 to 6.30   o 1.29 in patients of acute     
and chronic drug treatment, successively. Improvement in overall score was observed 
from 2.78 o 1.37 to 5.55   o 1.19, from 3.52   o 1.10 to 6.32   o 0.88 and from 4.49    o 
1.55 to 7.25 o 1.17 in educational group-1, group-2 and group-3 after counseling,         
respectively. CONCLUSIONS: Patients having low level of education, acute drug 
treatment and especially female patients know little about their prescribed drugs. 
Patient counseling about their prescribed drugs will help to improve the patient’s 
compliance and may lead to achieve better patient outcome.
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OBJECTIVES: The purpose of the current study is to evaluate the pharmaceutical 
industries’ situation and the effective factors in pharmaceutical products exportation 
in successful exporting countries and to compare the results with the situation of 
pharmaceutical industries in Iran and the factors affecting their exportation experi-
ences. METHODS: For the purposes of current cross-sectional study, an analytic 
questionnaire with open ended questions was designed which consisted of 32 questions 
in 8 ﬁelds. Subjects of the study consisted of 20 experts and ofﬁceholders of pharma-
ceutical industries and pharmaceutical products exporting companies and relevant 
governmental sections. Relevant information regarding pharmaceutical industries and 
